Key result
The authors recommend standardizing the nomenclature to 'vasoinhibin' for the family of antiangiogenic peptide hormones generated by proteolytic cleavage of prolactin, growth hormone, or placental lactogen.
This commentary updates the nomenclature for vasoinhibins, a family of antiangiogenic peptides derived from prolactin, growth hormone, and placental lactogen, to improve accuracy in scientific communication.
May aid cross-study comparisons in antiangiogenic research; leaves open effects on clinical translation.
No takes yet. Share an insight, caveat, or question.
Triebel et al. (2019) reported an editorial. Vasoinhibin nomenclature update was evaluated. The authors recommend standardizing the nomenclature to 'vasoinhibin' for the family of antiangiogenic peptide hormones generated by proteolytic cleavage of prolactin, growth hormone, or placental lactogen.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: